Pub Date : 2023-10-04DOI: 10.14450/2318-9312.v35.e3.a2023.pp243-246
Anselmo Gomes de Oliveira, Damaris Silveira
INFARMA – CIÊNCIAS FARMACÊUTICAS, SUA HISTÓRIA E OS10 ANOS DE SUA REFORMULAÇÃO E REAPRESENTAÇÃO PARACOMUNIDADE CIENTÍFICA
INFARMA -制药科学，它的历史和10年的重新制定和重新呈现给科学界
{"title":"INFARMA – CIÊNCIAS FARMACÊUTICAS, SUA HISTÓRIA E OS 10 ANOS DE SUA REFORMULAÇÃO E REAPRESENTAÇÃO PARA COMUNIDADE CIENTÍFICA","authors":"Anselmo Gomes de Oliveira, Damaris Silveira","doi":"10.14450/2318-9312.v35.e3.a2023.pp243-246","DOIUrl":"https://doi.org/10.14450/2318-9312.v35.e3.a2023.pp243-246","url":null,"abstract":"INFARMA – CIÊNCIAS FARMACÊUTICAS, SUA HISTÓRIA E OS10 ANOS DE SUA REFORMULAÇÃO E REAPRESENTAÇÃO PARACOMUNIDADE CIENTÍFICA","PeriodicalId":31004,"journal":{"name":"Infarma Pharmaceutical Sciences","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135592823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
O objetivo deste estudo foi avaliar a satisfação e perspectivas dos clientes sobre a qualidade do atendimento de um laboratório clínico privado acreditado. Um questionário de pesquisa de satisfação de clientes foi elaborado, validado e utilizado como ferramenta para avaliar a opinião de 319 participantes, selecionados aleatoriamente, em relação aos atributos da qualidade de um laboratório clínico privado. Os atributos avaliados em escala Likert foram analisados pelo ranking médio (RM) e os demais por estatística descritiva. A correlação entre os dados também foi avaliada estatisticamente. 59% dos participantes eram do sexo feminino, tinha entre 31 e 50 anos, foi ao laboratório para realizar exames de rotina e escolheu o laboratório por indicação médica. Os RM dos atributos da recepção e coleta foram, em escala Likert, superiores a 4,9. Na opinião dos clientes, o atributo que possui mais influência na escolha do laboratório clínico é a qualificação dos profissionais e o que menos interfere é a localização. Foi observado que os clientes mais velhos têm maior probabilidade de recomendar o laboratório. E que o tempo de espera é um dos pontos a serem melhorados. Ainda, 99% dos clientes estavam satisfeitos com os serviços do laboratório. Fato que não reflete, necessariamente, a qualidade técnica do laboratório, que é demonstrada pelos selos de qualidade e acreditação do laboratório clínico. Contudo, apenas 59% dos clientes relataram conhecimento do significado dos termos acreditação e selo de qualidade.
{"title":"SATISFAÇÃO E PERSPECTIVAS DO CLIENTE SOBRE A QUALIDADE DO ATENDIMENTO DE UM LABORATÓRIO CLÍNICO","authors":"Carolina Girard Hormann, Kênia Darós Zanette, Flavia Martinello","doi":"10.14450/2318-9312.v35.e3.a2023.pp394-406","DOIUrl":"https://doi.org/10.14450/2318-9312.v35.e3.a2023.pp394-406","url":null,"abstract":"O objetivo deste estudo foi avaliar a satisfação e perspectivas dos clientes sobre a qualidade do atendimento de um laboratório clínico privado acreditado. Um questionário de pesquisa de satisfação de clientes foi elaborado, validado e utilizado como ferramenta para avaliar a opinião de 319 participantes, selecionados aleatoriamente, em relação aos atributos da qualidade de um laboratório clínico privado. Os atributos avaliados em escala Likert foram analisados pelo ranking médio (RM) e os demais por estatística descritiva. A correlação entre os dados também foi avaliada estatisticamente. 59% dos participantes eram do sexo feminino, tinha entre 31 e 50 anos, foi ao laboratório para realizar exames de rotina e escolheu o laboratório por indicação médica. Os RM dos atributos da recepção e coleta foram, em escala Likert, superiores a 4,9. Na opinião dos clientes, o atributo que possui mais influência na escolha do laboratório clínico é a qualificação dos profissionais e o que menos interfere é a localização. Foi observado que os clientes mais velhos têm maior probabilidade de recomendar o laboratório. E que o tempo de espera é um dos pontos a serem melhorados. Ainda, 99% dos clientes estavam satisfeitos com os serviços do laboratório. Fato que não reflete, necessariamente, a qualidade técnica do laboratório, que é demonstrada pelos selos de qualidade e acreditação do laboratório clínico. Contudo, apenas 59% dos clientes relataram conhecimento do significado dos termos acreditação e selo de qualidade.","PeriodicalId":31004,"journal":{"name":"Infarma Pharmaceutical Sciences","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135592807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Yazdi, Kimia Shirmohammadi, E. Parvaneh, S. K. Hosseini, A. Ranjbar, M. Mehrpooya
Background: We assessed the potential efficacy of Coenzyme Q10 (CoQ10) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Methods: Seventy STEMI patients who presented ≤12 hours after the onset of symptoms and were scheduled for PPCI were randomly assigned to the standard treatments plus CoQ10 or placebo. In the intervention group, CoQ10, as an oral capsule at a dose of 400 mg, was loaded immediately before PPCI and continued at 200 mg twice daily for 28 days. The control group received a matching placebo, similarly. The study endpoints were the proportion of patients with complete myocardial reperfusion, defined as thrombolysis in myocardial infarction (TIMI) flow and myocardial blush grade (MBG) 3 at the end of PPCI, the proportion of patients with complete ST-segment elevation resolution (≥70%) assessed 60 minutes after PPCI, the plasma levels of creatine kinase myocardial band isoenzyme (CK-MB) and troponin I (TnI) at 12, 24, 48, and 72 hours after PPCI, and left ventricular ejection fraction (LVEF) at day 28. Results: The study groups were comparable regarding baseline clinical and procedural characteristics. The proportion of patients with TIMI flow grade 3, MBG 3, and complete ST resolution after completion of PPCI was similar between the groups. Whereas at all-time points after PPCI (12, 24, 48, and 72 hours), the plasma levels of CK-MB and TnI were significantly lower in the CoQ10 group than in the control group. Further, at day 28, CoQ10-treated patients exhibited better LVEF than placebo-treated patients, and the proportion of patients with LVEF less than 50% was lower in the intervention group than in the control group. Conclusion: Our study provided evidence that CoQ10 supplementation might reduce myocardial ischemia-reperfusion injury after PPCI and help to preserve left ventricular function. However, further studies are required to validate these results.
{"title":"Cardioprotective Effects of Coenzyme Q10 Supplementation on Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention","authors":"A. Yazdi, Kimia Shirmohammadi, E. Parvaneh, S. K. Hosseini, A. Ranjbar, M. Mehrpooya","doi":"10.34172/ps.2023.8","DOIUrl":"https://doi.org/10.34172/ps.2023.8","url":null,"abstract":"Background: We assessed the potential efficacy of Coenzyme Q10 (CoQ10) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Methods: Seventy STEMI patients who presented ≤12 hours after the onset of symptoms and were scheduled for PPCI were randomly assigned to the standard treatments plus CoQ10 or placebo. In the intervention group, CoQ10, as an oral capsule at a dose of 400 mg, was loaded immediately before PPCI and continued at 200 mg twice daily for 28 days. The control group received a matching placebo, similarly. The study endpoints were the proportion of patients with complete myocardial reperfusion, defined as thrombolysis in myocardial infarction (TIMI) flow and myocardial blush grade (MBG) 3 at the end of PPCI, the proportion of patients with complete ST-segment elevation resolution (≥70%) assessed 60 minutes after PPCI, the plasma levels of creatine kinase myocardial band isoenzyme (CK-MB) and troponin I (TnI) at 12, 24, 48, and 72 hours after PPCI, and left ventricular ejection fraction (LVEF) at day 28. Results: The study groups were comparable regarding baseline clinical and procedural characteristics. The proportion of patients with TIMI flow grade 3, MBG 3, and complete ST resolution after completion of PPCI was similar between the groups. Whereas at all-time points after PPCI (12, 24, 48, and 72 hours), the plasma levels of CK-MB and TnI were significantly lower in the CoQ10 group than in the control group. Further, at day 28, CoQ10-treated patients exhibited better LVEF than placebo-treated patients, and the proportion of patients with LVEF less than 50% was lower in the intervention group than in the control group. Conclusion: Our study provided evidence that CoQ10 supplementation might reduce myocardial ischemia-reperfusion injury after PPCI and help to preserve left ventricular function. However, further studies are required to validate these results.","PeriodicalId":31004,"journal":{"name":"Infarma Pharmaceutical Sciences","volume":"118 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73510239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Phytopharmaceuticals or herbal drugs have a significant therapeutic impact on healthcare systems. Though herbal extracts and their active constituents show excellent pharmacological in vitro effects, they still have indigent in vivo biological effects because of their considerable molecular weight and low lipid solubility, leading to low systemic availability. Phytosome is a novel approach for overcoming the drawbacks of conventional delivery methods of herbal actives. The phospholipids, mainly phosphatidylcholine, form a bond with herbal extracts or actives, forming a herb-lipid complex. The encapsulation of herbal actives with phospholipid allows an effective tool for the delivery to the affected area with enhanced pharmacological effect. Moreover, the amphiphilic nature of the phospholipid provides a good hydrophilic-lipophilic balance, thereby improving a better dissolution profile in the lipid-rich membranes of the gastrointestinal tract. This review focuses on the various phytosome nanocarriers to improve herbal medication bioavailability and uptake—recent trends in their industrial applicability, and applications in clinical management for various diseases, including other challenges.
{"title":"Recent Trends in Phytosome Nanocarriers for Improved Bioavailability and Uptake of Herbal Drugs","authors":"Hari Mahadevan, A. Kumaran","doi":"10.34172/ps.2023.6","DOIUrl":"https://doi.org/10.34172/ps.2023.6","url":null,"abstract":"Phytopharmaceuticals or herbal drugs have a significant therapeutic impact on healthcare systems. Though herbal extracts and their active constituents show excellent pharmacological in vitro effects, they still have indigent in vivo biological effects because of their considerable molecular weight and low lipid solubility, leading to low systemic availability. Phytosome is a novel approach for overcoming the drawbacks of conventional delivery methods of herbal actives. The phospholipids, mainly phosphatidylcholine, form a bond with herbal extracts or actives, forming a herb-lipid complex. The encapsulation of herbal actives with phospholipid allows an effective tool for the delivery to the affected area with enhanced pharmacological effect. Moreover, the amphiphilic nature of the phospholipid provides a good hydrophilic-lipophilic balance, thereby improving a better dissolution profile in the lipid-rich membranes of the gastrointestinal tract. This review focuses on the various phytosome nanocarriers to improve herbal medication bioavailability and uptake—recent trends in their industrial applicability, and applications in clinical management for various diseases, including other challenges.","PeriodicalId":31004,"journal":{"name":"Infarma Pharmaceutical Sciences","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80082024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Aslanabadi, E. Khani, Sajad Khiali, H. Rezaee, Saba Pishdad, Taher Entezari-Maleki
Background: Periprocedural myocardial injury (PMI) after percutaneous coronary intervention (PCI) is a substantial health issue with a high mortality rate. Inflammation and oxidative stress are major contributing factors to PMI. Allopurinol inhibits xanthine oxidase (XO)-induced oxidative stress and has potential cardiovascular benefits. Methods: This randomized clinical trial evaluated 110 patients admitted to elective PCI. Patients were assigned to receive either a 1200 mg loading dose of allopurinol 2 hours before the procedure (n = 55) or the standard pretreatment (n = 55). The creatine kinase-MB (CK-MB) and cardiac troponin I (cTnI) levels were measured in both groups at the baseline, 8, and 24 hours after PCI. Results: There were no significant differences in the CK-MB levels at baseline (P = 0.71), 8 (P = 0.26), and 24 hours (P = 0.88) after PCI between the two groups. No significant changes in the cTnI levels at baseline (P = 0.26), 8 (P = 0.80), and 24 hours (P = 0.89) after the PCI were also noted. The mean difference for CK-MB and cTnI changes was not different between the two groups. Conclusion: Our study revealed that allopurinol did not reduce cardiac-specific enzymes. Further studies are required to evaluate the impact of allopurinol on preventing PCI-related myocardial injury.
{"title":"Effects of Allopurinol in the Prevention of Periprocedural Myocardial Injury Following Elective Percutaneous Coronary Intervention: A Randomized Clinical Trial","authors":"N. Aslanabadi, E. Khani, Sajad Khiali, H. Rezaee, Saba Pishdad, Taher Entezari-Maleki","doi":"10.34172/ps.2023.3","DOIUrl":"https://doi.org/10.34172/ps.2023.3","url":null,"abstract":"Background: Periprocedural myocardial injury (PMI) after percutaneous coronary intervention (PCI) is a substantial health issue with a high mortality rate. Inflammation and oxidative stress are major contributing factors to PMI. Allopurinol inhibits xanthine oxidase (XO)-induced oxidative stress and has potential cardiovascular benefits. Methods: This randomized clinical trial evaluated 110 patients admitted to elective PCI. Patients were assigned to receive either a 1200 mg loading dose of allopurinol 2 hours before the procedure (n = 55) or the standard pretreatment (n = 55). The creatine kinase-MB (CK-MB) and cardiac troponin I (cTnI) levels were measured in both groups at the baseline, 8, and 24 hours after PCI. Results: There were no significant differences in the CK-MB levels at baseline (P = 0.71), 8 (P = 0.26), and 24 hours (P = 0.88) after PCI between the two groups. No significant changes in the cTnI levels at baseline (P = 0.26), 8 (P = 0.80), and 24 hours (P = 0.89) after the PCI were also noted. The mean difference for CK-MB and cTnI changes was not different between the two groups. Conclusion: Our study revealed that allopurinol did not reduce cardiac-specific enzymes. Further studies are required to evaluate the impact of allopurinol on preventing PCI-related myocardial injury.","PeriodicalId":31004,"journal":{"name":"Infarma Pharmaceutical Sciences","volume":"53 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90748793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The overcomplicated and elusive pathophysiology with unclear etiology, have been the main driving force of the medical scientists all over the world to develop a predictive, reliable, robust and reproducible simulation model of arthritis. This review highlights the osteoarthritis and rheumatoid arthritis with distinct conditions pertaining to each type of disease. The advances in various in vitro and in vivo experimental models of osteoarthritis and rheumatoid arthritis have been presented along with their pros and cons for antiarthritic drug discovery and formulation development. Additionally, the ethical issues to be considered while selecting animal models and handling them have been covered briefly. The current status quo on clinical trials of antiarthritic therapeutic interventions has also been covered.
{"title":"Role of preclinical arthritis models for the clinical translation of anti-arthritic therapeutics","authors":"L. R. Singha, M. K. Das","doi":"10.34172/ps.2023.7","DOIUrl":"https://doi.org/10.34172/ps.2023.7","url":null,"abstract":"The overcomplicated and elusive pathophysiology with unclear etiology, have been the main driving force of the medical scientists all over the world to develop a predictive, reliable, robust and reproducible simulation model of arthritis. This review highlights the osteoarthritis and rheumatoid arthritis with distinct conditions pertaining to each type of disease. The advances in various in vitro and in vivo experimental models of osteoarthritis and rheumatoid arthritis have been presented along with their pros and cons for antiarthritic drug discovery and formulation development. Additionally, the ethical issues to be considered while selecting animal models and handling them have been covered briefly. The current status quo on clinical trials of antiarthritic therapeutic interventions has also been covered.","PeriodicalId":31004,"journal":{"name":"Infarma Pharmaceutical Sciences","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84438728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Homa Rezaei, M. Kuentz, Hongkun Zhao, E. Rahimpour, A. Jouyban
Background: There is only limited data for solubility of codeine phosphate in binary systems available, which comes with uncertainties about the prediction accuracy of common thermodynamic models. Methods: This study investigated the codeine phosphate dissolution in N-methyl-2-pyrrolidone (NMP) and ethanol system using shake-flask method and mathematically described generated data by different thermodynamic models. The density as another property were also determined and fitted to results of the Jouyban-Acree equation. The mean relative deviations were obtained for confirming the model’s accuracy. Moreover, ,, and of the dissolution of codeine phosphate in the NMP and ethanol system were calculated using the desired equations at Thm. Results: The dissolution process of codeine phosphate was identified as endotherm, the solubility in the binary mixtures was best at higher mass fractions of NMP and finally, the model predictions were deemed as excellent based on a mean relative deviation that was generally below eight percent. Conclusion: The results of this study could expand the available solubility database for codeine phosphate.
{"title":"Experimental, Modeling and Molecular Dynamics Simulation of Codeine Phosphate Dissolution in N-Methyl-2-pyrrolidone + Ethanol","authors":"Homa Rezaei, M. Kuentz, Hongkun Zhao, E. Rahimpour, A. Jouyban","doi":"10.34172/ps.2023.2","DOIUrl":"https://doi.org/10.34172/ps.2023.2","url":null,"abstract":"Background: There is only limited data for solubility of codeine phosphate in binary systems available, which comes with uncertainties about the prediction accuracy of common thermodynamic models. Methods: This study investigated the codeine phosphate dissolution in N-methyl-2-pyrrolidone (NMP) and ethanol system using shake-flask method and mathematically described generated data by different thermodynamic models. The density as another property were also determined and fitted to results of the Jouyban-Acree equation. The mean relative deviations were obtained for confirming the model’s accuracy. Moreover, ,, and of the dissolution of codeine phosphate in the NMP and ethanol system were calculated using the desired equations at Thm. Results: The dissolution process of codeine phosphate was identified as endotherm, the solubility in the binary mixtures was best at higher mass fractions of NMP and finally, the model predictions were deemed as excellent based on a mean relative deviation that was generally below eight percent. Conclusion: The results of this study could expand the available solubility database for codeine phosphate.","PeriodicalId":31004,"journal":{"name":"Infarma Pharmaceutical Sciences","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88781869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nour Awada, A. Ayoub, A. Jaber, Farah Ibrahim, Nadine El Ghotmi, Edmond Cheble
Background: Screening of medicinal plants for their biological activities and phytochemicals is important for finding safe and potent new compounds for therapeutic use. The current investigation was conducted in extracts of Lebanese A. squamosa (leaves and bark) to evaluate the antioxidant, anticancer, and anti-inflammatory activities. Methods: Seven extracts were prepared by ultrasound-assisted extraction (UAE) or microwave-assisted extraction (MAE), and using various solvents. The evaluation of antioxidant activity was done using DPPH assay, the anticancer activity assessed on the colon cancer HCT116 cell line was determined by WST-1 viability assay, and finally the anti-inflammatory activity was investigated by measuring the secreted amounts of PGE2 and IL-6 using. Results: The TPC were in the range between 27.3 to 179.5 mg GAE/g of plant extract, while TFC were between 8.3 to 150.8 mg RE/g of plant extract. DPPH assay showed high antioxidant activity for the methanolic extracts obtained by UAE in both natural dried leaves and bark with IC50 values of 9.3 and 12.6 μg.mL-1, respectively. For WST-1 assay, methanolic extracts obtained by UAE showed a potent anti-proliferative effect against HCT116 cell line with IC50 values ranged from 0.18 to 0.88 μg.mL-1. Also, the western blot assay suggested that these extracts may inhibit the proliferation of HCT 116 cell line by causing cell cycle arrest through activation of p21 pathway. Significant anti-inflammatory activity was observed due to the decrease in the secretion of IL-6 in LPS-stimulated THP-1 cells. Conclusion: Therefore, the present study revealed that the dried leaves and bark of Lebanese A. squamosa methanolic extracts obtained by UAE possess effective bioactivities, thus hold potential application in the pharmacological field.
{"title":"Evaluation of the anticancer, anti-inflammatory, and antioxidant properties of various extracts of Annona squamosa L.","authors":"Nour Awada, A. Ayoub, A. Jaber, Farah Ibrahim, Nadine El Ghotmi, Edmond Cheble","doi":"10.34172/ps.2023.5","DOIUrl":"https://doi.org/10.34172/ps.2023.5","url":null,"abstract":"Background: Screening of medicinal plants for their biological activities and phytochemicals is important for finding safe and potent new compounds for therapeutic use. The current investigation was conducted in extracts of Lebanese A. squamosa (leaves and bark) to evaluate the antioxidant, anticancer, and anti-inflammatory activities. Methods: Seven extracts were prepared by ultrasound-assisted extraction (UAE) or microwave-assisted extraction (MAE), and using various solvents. The evaluation of antioxidant activity was done using DPPH assay, the anticancer activity assessed on the colon cancer HCT116 cell line was determined by WST-1 viability assay, and finally the anti-inflammatory activity was investigated by measuring the secreted amounts of PGE2 and IL-6 using. Results: The TPC were in the range between 27.3 to 179.5 mg GAE/g of plant extract, while TFC were between 8.3 to 150.8 mg RE/g of plant extract. DPPH assay showed high antioxidant activity for the methanolic extracts obtained by UAE in both natural dried leaves and bark with IC50 values of 9.3 and 12.6 μg.mL-1, respectively. For WST-1 assay, methanolic extracts obtained by UAE showed a potent anti-proliferative effect against HCT116 cell line with IC50 values ranged from 0.18 to 0.88 μg.mL-1. Also, the western blot assay suggested that these extracts may inhibit the proliferation of HCT 116 cell line by causing cell cycle arrest through activation of p21 pathway. Significant anti-inflammatory activity was observed due to the decrease in the secretion of IL-6 in LPS-stimulated THP-1 cells. Conclusion: Therefore, the present study revealed that the dried leaves and bark of Lebanese A. squamosa methanolic extracts obtained by UAE possess effective bioactivities, thus hold potential application in the pharmacological field.","PeriodicalId":31004,"journal":{"name":"Infarma Pharmaceutical Sciences","volume":"30 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82983204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Samin Mohammadi, B. Jafari, Samira Pourtaghi Anvarian, H. Nazemiyeh, S. Asnaashari, A. Delazar, P. Asgharian
Phlomoides (L.) Moench belongs to the Lamiaceae family. It has recently undergone significant changes in taxonomy, with many species from Eremostachys and Phlomis added to the genus. The aforementioned species were studied in terms of morphological and phytochemical systematics. Species of Phlomoides are distinguished from Phlomis by their densely bearded upper corolla lip and nutlet. However, Eremostachys and Phlomoides have a lot in common morphologically. Plant chemosystematics present iridoids, phenylethanoids, and furanolabdanes as dominant constituents of Phlomoides species. Long-term traditional uses, such as bone fracture therapy, local analgesic, and wound healing actions, pique researchers' interest in these plants. The species and their secondary metabolites have been implicated in drug discovery by their anti-inflammatory and bone-development properties in vitro, in vivo, and clinically. A review of the taxonomic status based on phytochemical and morphological characteristics, as well as the clinical importance of the Phlomoides genus, is presented in the current study to provide a basis for further investigations.
{"title":"Taxonomic revision and clinical importance of Phlomoides genus: A comprehensive review","authors":"Samin Mohammadi, B. Jafari, Samira Pourtaghi Anvarian, H. Nazemiyeh, S. Asnaashari, A. Delazar, P. Asgharian","doi":"10.34172/ps.2023.1","DOIUrl":"https://doi.org/10.34172/ps.2023.1","url":null,"abstract":"Phlomoides (L.) Moench belongs to the Lamiaceae family. It has recently undergone significant changes in taxonomy, with many species from Eremostachys and Phlomis added to the genus. The aforementioned species were studied in terms of morphological and phytochemical systematics. Species of Phlomoides are distinguished from Phlomis by their densely bearded upper corolla lip and nutlet. However, Eremostachys and Phlomoides have a lot in common morphologically. Plant chemosystematics present iridoids, phenylethanoids, and furanolabdanes as dominant constituents of Phlomoides species. Long-term traditional uses, such as bone fracture therapy, local analgesic, and wound healing actions, pique researchers' interest in these plants. The species and their secondary metabolites have been implicated in drug discovery by their anti-inflammatory and bone-development properties in vitro, in vivo, and clinically. A review of the taxonomic status based on phytochemical and morphological characteristics, as well as the clinical importance of the Phlomoides genus, is presented in the current study to provide a basis for further investigations.","PeriodicalId":31004,"journal":{"name":"Infarma Pharmaceutical Sciences","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88690921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：